CTOs on the Move

Norbrook

www.norbrook.com

 
Norbrook® is a true innovator and dedicated to novel research and revolutionary processes and products. Lord Ballyedmond, Founder, Chairman and CEO of the Norbrook Group began his career in the pharmaceutical industry in the USA in the 1960s and now controls the largest privately owned pharmaceutical company in the world.    The company is very active in both medical and veterinary products.    Research and Development is the key to Norbrook`s success with the R&D Department central to the company`s structure. It is responsible for new product development, technical support and meeting regulatory and licensing protocols. Norbrook invests more than 10% of its turnover ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $50-100 Million
  • www.norbrook.com
  • 9733 Loiret Boulevard
    Lenexa, KS USA 66219
  • Phone: 913.599.5777

Executives

Name Title Contact Details

Similar Companies

Hikma Pharmaceuticals

At Hikma we put better health within reach, every day. We create high quality medicines, and we make them accessible and affordable to the people who need them.

CHEMINPHARMA

CHEMINPHARMA is a Farmington, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Human Care Systems, Inc.

HCS designs and delivers technology driven therapy management to improve patient initiation, adherence, and persistence. Since 2008, HCS has worked with biopharma brand teams who want to deliver personalized, omni-channel programming with measured outcomes.

Nanōmix

Nanōmix is the leader in mobile point-of-care diagnostics for use where time and accuracy is critical.

Momenta Pharmaceuticals

Momenta is a biotechnology company with a product pipeline of both complex mixture generic and novel drugs. Our complex mixture generics and follow-on biologics effort is focused on building a thorough understanding of the structure-process-activity of complex mixture drugs to develop generic versions of marketed products. While we use a similar analytical and development approach across all of our product candidates, we tailor that approach for each specific product candidate. Our first objective is to apply our core analytical technology to thoroughly characterize the structure of the marketed product. By defining the chemical composition of multiple batches of a marketed product, we are able to develop an equivalence window which captures the inherent variability of the innovator`s manufacturing process. Using this information, we then build an extensive understanding of the structure-process relationship to design and control our manufacturing process to manufacture reproducibly an equivalent version of the marketed product. Where necessary, and as required by the U.S. Food and Drug Administration, or FDA, we will supplement an application with additional supportive structure-activity data (e.g., immunogenicity, pharmacodynamics). Our goal is to obtain FDA approval for and commercialize generic or follow-on versions of complex mixture products, thereby providing high quality, safe and affordable medicines to patients in need.